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Abstract
Primary diffuse large B-cell lymphoma of the central nervous system (CNS DLBCL)
is a rare, aggressive subtype of DLBCL, the biology of which is poorly understood.
Recent studies have suggested a prognostic role of MYC protein expression in
systemic DLBCL, but little is known about the frequency and significance of MYC
protein expression in CNS DLBCL. Hence, we investigated MYC protein
expression profiles of CNS DLBCL and assessed the relationship between MYC
expression and a variety of histopathologic, immunophenotypic, genetic, and
clinical features. Fifty-nine CNS DLBCL diagnosed at our institution over the past
13 years were evaluated. The majority of cases (80%) showed centroblastic
morphology, and 12 (20%) displayed a perivascular pattern of infiltration. According
to the Hans criteria, 41 (69%) cases had a non-germinal center B-cell and 18 (31%)
had a germinal center B-cell cell-of-origin (COO) phenotype. Mean MYC protein
expression was 50% (median: 50%, range: 10-80%). Forty-three cases (73%)
showed MYC overexpression (>40%), and 35 (60%) showed MYC/BCL2
coexpression. MYC overexpression was seen in the single case harboring MYC
translocation and in the cases showing increased copies of MYC (27%); however,
no significant difference in mean MYC expression was seen between groups
harboring or lacking MYC aberrations. In our series, age was associated with a
significantly increased risk of death, and the perivascular pattern of infiltration was
associated with a significantly increased risk of disease progression. Neither MYC
expression (with or without BCL2 coexpression) nor other variables, including COO
subtype were predictive of clinical outcome. Our findings indicate that the
proportion of CNS DLBCL overexpressing MYC is higher compared to systemic
DLBCL, and MYC overexpression appears to be independent of genetic MYC
OPEN ACCESS
Citation: Gill KZ, Iwamoto F, Allen A, Hoehn D,
Murty VV, et al. (2014) MYC Protein Expression in
Primary Diffuse Large B-Cell Lymphoma of the
Central Nervous System. PLoS ONE 9(12):
e114398. doi:10.1371/journal.pone.0114398
Editor: Renato Franco, Istituto dei tumori
Fondazione Pascale, Italy
Received: June 26, 2014
Accepted: November 6, 2014
Published: December 5, 2014
Copyright:  2014 Gill et al. This is an open-
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and repro-
duction in any medium, provided the original author
and source are credited.
Data Availability: The authors confirm that all data
underlying the findings are fully available without
restriction. All relevant data are within the paper
and its Supporting Information files.
Funding: This study was funded by intramural
funds from the Columbia University Medical Center
Department of Pathology and Cell Biology. The
funders had no role in study design, data collection
and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
PLOS ONE | DOI:10.1371/journal.pone.0114398 December 5, 2014 1 / 17
abnormalities. Thus, MYC expression and other immunophenotypic markers used
for prognostication of systemic DLBCL might not apply to CNS DLBCL due to
differences in disease biology.
Introduction
Primary diffuse large B-cell lymphoma of the central nervous system (CNS
DLBCL) is a subtype of diffuse large B-cell lymphoma (DLBCL) arising in the
brain or an intraocular location. Exclusion criteria for diagnosis according to the
2008 WHO classification include dural involvement, intravascular large B-cell
lymphoma, immunodeficiency-associated lymphoma, and secondary lymphoma
[1]. CNS DLBCL is rare, accounting for,1% of all non-Hodgkin lymphomas and
approximately 3% of all primary brain neoplasms [2]. Compared to systemic
DLBCL, CNS DLBCL has a poor prognosis, and it remains unclear whether this
reflects a location specific or microenvironmental effect, inherent aggressive
biology of the tumor, or a combination of these factors. The cell-of-origin (COO)
of CNS DLBCL is thought to be a late germinal center B-cell based on
immunophenotypic analysis, gene expression profiling, and molecular char-
acterization of the immunoglobulin genes [3, 4]. The biology of CNS DLBCL is
poorly understood due to its rarity and, in part, due to difficulty in obtaining
sufficient tumor samples.
MYC is a pleiotropic transcription factor that has important roles in diverse
cellular processes, ranging from the regulation of cell size, survival, proliferation,
metabolism, and signal transduction to control of DNA replication. It is also a
potent oncogene, and deregulation ofMYC expression due to genetic lesions (e.g.,
translocations, amplifications, and mutations) or other mechanisms is one of the
more common alterations in cancer, having been implicated in the pathogenesis
of many types of human neoplasms including a variety of solid tumors and
lymphoid malignancies [5]. Recent studies have described the utility of
cytogenetic and FISH analyses in characterizing MYC aberrations, which can aid
in distinguishing between Burkitt lymphoma and other types of aggressive B-cell
lymphomas [6]. MYC rearrangements have been reported in 10–15% of systemic
DLBCL, and they have been associated with a poor prognosis either alone or in
combination with BCL2 rearrangements (‘‘double-hit’’ lymphomas) [7–9].
DLBCL displaying high MYC protein expression have also been shown to have an
adverse prognosis independent of MYC rearrangement and COO subtype [10–
12]. The incidence of MYC rearrangements has been reported to be slightly lower
in CNS DLBCL (3–8%), and limited data thus far have not shown any prognostic
impact of these rearrangements [13, 14]. MYC mutations bearing the molecular
hallmarks of aberrant somatic hypermutation have also been detected in CNS
DLBCL, but their clinical significance is unknown at present [15]. Increased
transcripts of MYC and MYC-induced genes involved in cell survival and
MYC Protein Expression in Primary Central Nervous System Lymphoma
PLOS ONE | DOI:10.1371/journal.pone.0114398 December 5, 2014 2 / 17
proliferation were reported by gene expression profiling of CNS DLBCL
compared to nodal DLBCL, potentially implicating MYC deregulation in disease
pathogenesis [16]. Data regarding MYC protein expression in CNS DLBCL are
limited, with disparate frequencies of expression having been reported (0–92%)
[13, 17, 18]. Importantly, the association, if any, of MYC expression levels with
biological and clinical features has not been established in CNS DLBCL. Thus, we
sought to determine MYC protein expression profiles of a large series of CNS
DLBCL diagnosed and treated at our institution to investigate the association
between MYC protein expression and a variety of histopathologic, immunophe-
notypic, and clinical features. Cytogenetic and FISH analyses to assess




This study was performed in accordance with the regulations of the Columbia
University Human Research Protection Program and a protocol approved by the
Institutional Review Board of Columbia University, New York, USA. All patients
provided written informed consent for use of tissue samples for clinical research,
and the study was conducted according to the principles expressed in the
Declaration of Helsinki.
Case selection
We searched our departmental database for all cases of DLBCL involving the CNS
diagnosed over the past 14 years. The 2008 WHO criteria were used to classify
cases as CNS DLBCL after excluding lymphomas associated with immunodefi-
ciency (e.g., HIV infection or post-organ transplantation), those arising in or
involving the dura, cases with prior or concurrent low-grade B-cell lymphomas,
and secondary CNS involvement by systemic DLBCL [1]. Cases with insufficient
material to allow adequate interpretation of immunohistochemical stains were
also excluded. Clinical and radiographic data were obtained from the electronic
medical record system or from patient charts by the neurooncologist (FI).
Morphology
H&E-stained sections were used for cytomorphologic evaluation. Patterns of
neoplastic cell infiltration were classified as either 1) perivascular (neoplastic
lymphocytes localized around blood vessels with only limited parenchymal
infiltration) or 2) diffuse (large aggregates or sheet-like infiltrates of neoplastic
lymphocytes).
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Immunohistochemistry
The antibodies used included CD10 (monoclonal mouse anti-human antibody,
clone 56C6, predilute, Novocastra, Buffalo Grove, IL), BCL6 (monoclonal mouse
anti-human antibody, clone LN22, predilute, Novocastra, Buffalo Grove, IL),
MUM1/IRF4 (monoclonal rabbit anti-human antibody, clone MRQ-43, predilute,
Dako, Carpinteria, CA), BCL2 (monoclonal mouse anti-human antibody, clone
bcl-2/100/D5, predilute, Novocastra, Buffalo Grove, IL), MIB-1 (monoclonal
rabbit anti-human antibody, clone 30-9, predilute, DAKO, Carpinteria, CA), and
C-MYC (monoclonal mouse anti-human antibody, clone 9E10, dilution 1:100,
Epitomics Inc., Burlingame, CA). Staining was performed with an automated
staining machine (Universal Staining System, DAKO) after moist heat induced
antigen retrieval, and Envision Plus (DAKO) was used for visualization with
Diaminobenzidine as the chromogen, according to standard protocols. The
percentage of tumor cells expressing the aforementioned markers was recorded in
deciles by two pathologists (KG and GB), and the COO subtype was determined
using the Hans criteria [19].
Cytogenetic analysis
G-band karyotype analysis was performed on metaphase preparations of fresh
tumor specimens, where available, after unstimulated overnight cultures, and
karyotypes were described according to the International System for Human
Cytogenetic Nomenclature [20]. FISH was performed on formalin fixed paraffin
embedded tissue according to standard protocols using LSI c-MYC break-apart
probes (Abbott Molecular, Des Moines, IL, USA). Fluorescence signals were
captured after counterstaining with 49,6-diamidino-2-phenylindole (DAPI) using
the Cytovision Imaging system attached to a Nikon Eclipse 600 microscope
(Applied Imaging, Santa Clara, CA, USA). The range of normal variation (95%
confidence interval) of the c-MYC probe was 1.0+0.6% cells showing MYC breaks
in formalin-fixed, paraffin-embedded control (tonsil) tissue. Hybridization signals
were interpreted by two observers (KG and VM) in all cases.
Statistical analysis
Chi-square, Fisher’s exact, and Student’s t-tests were used to compare
histopathologic, immunophenotypic, and clinical variables as appropriate.
Pearson’s correlation was used to compare percentage MYC expression and the
Ki-67 proliferation index. Univariate and multivariate logistic regression models
were used to analyze risk of disease progression and death associated with
pathological and clinical variables. Progression-free (PFS) and overall survival
(OS) were evaluated using Kaplan Meier analysis with a log rank comparison.
Survival analyses were restricted to the patients receiving treatment and follow up
at our institution. A p-value ,0.05 was considered significant for all analyses.
Statistical analysis was performed as applicable with the following software: SPSS
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version 20 (IBM, Armonk, NY), Excel (Microsoft, Redmond, WA), and Prism
(Graph Pad, La Jolla, CA).
Results
Clinical characteristics
Fifty-nine cases of CNS DLBCL met our selection criteria. The median age of
patients at diagnosis was 65 years (range: 37–87 years), and 24 (41%) were male.
Pertinent clinical features are listed in Table 1, and the complete data set is
provided in Table S1. On imaging, 50 (88%) cases were supratentorial, and 24
(41%) showed involvement of deep-brain structures (i.e., brain stem, cerebellum,
basal ganglia, corpus callosum, or the ventricles). Thirty of 57 (53%) patients with
available data had multiple tumors. LDH levels at diagnosis were elevated in 16 of
23 (70%) patients with available data. The median Karnofsky Performance Status
(KPS) was 70% (range: 20–90%), and 34 of 58 (59%) patients with available data
had ECOG scores >2. CSF protein levels were unavailable for the vast majority of
cases. Forty-three of 48 (90%) patients with available treatment data received
therapy. Twenty-seven (63%) patients received methotrexate monotherapy, while
13 (30%) received rituximab and 7 (16%) received whole brain radiation therapy
(WBRT) in addition to chemotherapy. The untreated patients died before
initiation of treatment, refused treatment, or were not treated due to their overall
medical condition. Details of the therapeutic modalities are listed in Table 1.
Of the treated patients with follow-up information, median OS was 14.1
months and median PFS was 6.0 months. Lymphoma was the cause of death for
all patients followed until death. Twenty-one patients (36%) were lost to follow
up and 10 patients (17%) were still alive at the time of data collection. The follow-
up time of the latter ranged from ,1 month to 128 months (mean: 22 months,
median: 9 months).
Morphology
Forty-seven (80%) cases were classified as centroblastic, two of which exhibited
signet ring cell features; 2 (3%) were immunoblastic; 1 (2%) was anaplastic; four
(7%) exhibited plasmacytoid morphology; and 5 (8%) had morphologic features
intermediate between DLBCL and Burkitt lymphoma (representative cases are
illustrated in Figure 1). Twelve cases (20%) showed a perivascular pattern of
infiltration, and the remainder showed a diffuse pattern (representative examples
are shown in Figure 2).
Immunohistochemistry
Using the Hans criteria, 41 (69%) cases had a non-GCB COO phenotype (CD10-/
BCL6-/MUM1/IRF4+, n54; CD10-/BCL6+/MUM1/IRF4+, n537) and 18 (31%)
had a GCB COO phenotype (CD10+/BCL6+/MUM1/IRF4-, n54; CD10-/BCL6+/
MUM1/IRF4-, n56; and CD10+/BCL6+/MUM1/IRF4+, n58). Of the cases with
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morphologic features intermediate between DLBCL and Burkitt lymphoma, four
had a non-GCB and one had a GCB COO phenotype. The median Ki-67
proliferation index was 70% (mean: 68%, range: 20–100%), and the median MYC
expression was 50% (mean: 50%, range: 10–80%) (representative examples are
shown in Figures 1 and 2). No significant difference in mean MYC expression was
noted between cases manifesting non-GCB and GCB COO phenotypes (52% vs.
46%, respectively, p50.14). There was no significant difference in MYC
expression between cases exhibiting perivascular and diffuse patterns of
infiltration. A weak positive correlation was noted between MYC expression and
Table 1. Clinical Characteristics of CNS DLBCL.
Variable Result
Age at diagnosis (years) Median: 66, range: 37–87
Sex (males) 24/59 (41%)
KPS Median: 70%, range: 20–90%
ECOG Mean: 2, cases >2: 34/58 (59%)




Number of tumor masses:
Single 27/57 (47%)
Multiple 30/57 (53%)





MTX, WBRT 1/43 (2%)
MTX, rituximab 1/43 (2%)
R-MVP 2/43 (5%)
R-MVP, WBRT 1/43 (2%)
R-MVP, cytarabine 4/43 (9%)
R-MVP, cytarabine, WBRT 2/43 (5%)
MTX, rituximab, temozolamide 1/43 (2%)
MTX, rituximab, temozolamide, WBRT 1/43 (2%)
MTX, rituximab, procarbazine, WBRT 1/43 (2%)
MVP, cytarabine, temozolamide 1/43 (2%)
MTX, thiotepa 1/43 (2%)
MTX, taxol, WBRT 1/43 (2%)
No therapy 5/48 (10%)
Abbreviations: MXT, methotrexate. WBRT, whole brain radiation therapy. R-MVP, rituximab, methotrexate,
procarbazine, and vincristine.
*Normal range of LDH: 115–221 units/L.
doi:10.1371/journal.pone.0114398.t001
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Figure 1. Representative examples of CNS DLBCL harboring or lacking chromosome 8/MYC aberrations. H&E-stained section of a case exhibiting
morphologic features intermediate between DLBCL and Burkitt lymphoma (A), 80% MYC expression by the neoplastic cells (B), non-GCB COO subtype -
BCL6+ (C) and MUM1/IRF4+ (D), and displaying two normal MYC loci by FISH (two fused signals) (E). H&E-stained section of a case showing
immunoblastic morphology (F), 50% MYC expression by the neoplastic cells (G), non-GCB COO subtype - BCL6+ (H) and MUM1/IRF4+ (I), and displaying
MYC rearrangement by FISH (one split signal, red and green, and one fused signal) (J). H&E-stained section of a DLBCL showing anaplastic morphology
(K), 60% MYC expression by the neoplastic cells (L), GCB COO subtype - CD10+ (M) and BCL6+ (N), and increased copies of MYC by FISH (5 fused
signals) (O). Photomicrographs of all H&E-stained sections were taken at 400x magnification and all others at 40x magnification.
doi:10.1371/journal.pone.0114398.g001
Figure 2. Representative examples of patterns of CNS DLBCL infiltration and MYC protein expression.
H&E-stained section of a CNS DLBCL exhibiting a diffuse pattern of infiltration (A), CD20 expression (B), and
MYC expression by 80% of neoplastic cells (C). H&E-stained section of a CNS DLBCL exhibiting a
perivascular pattern of infiltration (D), CD20 expression (E), and MYC expression by 30% of neoplastic cells
(F). All photomicrographs were taken at 40x magnification.
doi:10.1371/journal.pone.0114398.g002
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the Ki-67 proliferation index (r50.3). Using cutoffs for MYC and BCL2 positivity
of >40% and >70%, respectively (similar to cutoffs used in prior studies of
systemic DLBCL [10, 21]), 43 (73%) cases were considered as overexpressing
MYC and denoted MYC+, 41 (71%) were considered BCL2+, and 35 (60%) were
considered MYC+ and BCL2+ (‘‘double positive’’). The proportion of MYC+
cases was not significantly different between the non-GCB and GCB COO
subtypes (76% vs. 67%, respectively, p50.53). However, the proportion of BCL2+
cases was significantly higher in the non-GCB compared to the GCB COO subtype
(83% vs. 41%, respectively, p,0.005), and there was a trend toward a higher
proportion of MYC and BCL2 double positive cases in the non-GCB compared to
the GCB COO subtype (68% vs. 41%, respectively, p50.08).
Cytogenetic analysis
G-band karyotypes to assess 8q24 aberrations and/or FISH to assess MYC
aberrations were performed in 31 of 59 cases (53%). Informative results were
obtained in 16 of 31 cases (52%). Karyotypes were obtained in 8 of 12 (67%)
cases, and successful FISH analyses were obtained in 11 of 24 (46%) cases; 3 cases
had both a successful karyotype and FISH analysis. Of the cases with karyotypes,
all except one showed complex karyotypes. Deletion of 6q was the most frequent
recurrent abnormality, observed in three (38%) cases. Other recurrent changes,
each observed in two cases, were dup(1q), add(14)(q32), add(15)(p11.2), +3, +7,
+13, and +21. No case exhibited 8q24 rearrangement by karyotype. Of the 11 cases
with informative FISH analyses, one (9%) showed MYC rearrangement and three
(27%) showed increased copies of MYC (mean MYC copies/cell: 3, 4, and 6) (see
Figure 1 for examples). Two of the cases with increased copies of MYC had
polyploid karyotypes (1 triploid and 1 tetraploid); the third case did not have a
successful karyotype to determine the mechanism of MYC copy number increase.
MYC protein expression was 50% in the case with MYC rearrangement and was
60–80% in the cases showing increased copies of MYC. Mean MYC protein
expression in the group comprising cases with MYC rearrangement or increased
MYC copies was not significantly different from the group lacking these
abnormalities (68% vs. 64%, respectively, p.0.1).
Association of morphologic, phenotypic, and clinical parameters
with outcomes
Analysis of clinical outcomes was restricted to the 43 patients who received
therapy at our institution. The perivascular pattern of infiltration was associated
with a significantly higher risk of disease progression (odds ratio: 5.09, p,0.05)
and a trend toward shorter PFS (p50.09; Figure 3). No significant differences in
PFS or OS were observed according to the cytomorphologic subtype of DLBCL,
individual marker expression (i.e., CD10, BCL6, or MUM1/IRF4), COO subtype,
or Ki-67 proliferation index (all p-values .0.1). MYC and/or BCL2 expression
were analyzed for impact on survival using all possible deciles as cutoffs and in
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PLOS ONE | DOI:10.1371/journal.pone.0114398 December 5, 2014 8 / 17
subsets of patients receiving rituximab or WBRT, but no significant associations
were observed.
Older age was associated with a significantly increased risk of death (odds ratio:
1.09, p,0.005), while rituximab therapy was associated with a significantly
decreased risk of death (odds ratio: 0.04, p,0.005). Individuals receiving WBRT
showed a trend toward lower risk of disease progression (odds ratio: 0.2, p50.06)
and decreased risk of death (odds ratio: 0.07, p50.07). Of note, significant
associations of older age with increased risk of death and rituximab with
decreased risk of death persisted when analyzing MYC+ and MYC- cases
independently. No significant differences in survival were noted when other
individual components of the International Extranodal Lymphoma Study Group
scoring system (i.e., involvement of deep brain structures, LDH level, and
performance scores) were analyzed [22].
On multivariate analysis, older age showed a trend toward increased risk of
death (odds ratio: 1.08, p50.06), rituximab retained a significant association with
decreased risk of death (odds ratio: 0.06, p50.02), and perivascular pattern of
Figure 3. Survival curve showing a trend toward shorter progression-free survival of CNS DLBCL
manifesting a perivascular pattern of infiltration.
doi:10.1371/journal.pone.0114398.g003
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infiltration retained a significant association with a higher risk of progression
(odds ratio: 0.06, p,0.05). WBRT showed neither significant differences nor
trends toward decreased risk of progression or death in multivariate analysis. See
Table S2 for detailed results of statistical analyses with associated p values.
Discussion
We evaluated MYC protein expression in conjunction with a variety of
morphologic, immunophenotypic, genetic, and clinical parameters in a large
single-center series of CNS DLBCL to determine whether MYC protein expression
could serve as a prognostic or theranostic biomarker. Similar to prior reports, our
CNS DLBCL predominantly displayed centroblastic morphology and the non-
GCB COO phenotype (69%). MYC overexpression (>40%) was noted in 73% of
our cases, which is slightly lower that the frequency recently reported by Brunn et
al. (92%) but still higher than that described in systemic DLBCL (approximately
30–50%) [9, 10, 12]. Differences in the frequencies of MYC expression between
CNS and systemic DLBCL may be related to the predominance of the non-GCB
COO subtype in CNS DLBCL, as MYC expression is higher in the ABC (or non-
GC) COO subtype of systemic DLBCL [10, 12]. Importantly, in contrast to recent
studies of systemic DLBCL [10–12], we did not find any association of MYC
expression, MYC/BCL2 coexpression, or COO subtype with adverse clinical
features or survival. A decreased risk of death was noted in patients receiving
rituximab treatment, and an increased risk of disease progression was observed in
cases exhibiting a perivascular pattern of infiltration.
The underlying genetic and molecular basis for MYC protein expression in CNS
DLBCL is currently unclear. The reported frequencies of MYC rearrangement in
CNS DLBCL (3–8% in prior studies and 9% in our study) are slightly lower than
those reported in systemic DLBCL (10–15%) [7–9, 13, 14]. MYC overexpression
in a subset of our cases showing increased copies of MYC (27%), due to
chromosome 8 polysomy, could suggest a dosage effect of the MYC gene as an
explanation for MYC overexpression in some instances. Increased copies of
chromosome 8 have been shown to correlate with increased MYC transcripts in
certain myeloid malignancies, but this relationship has not yet been established in
lymphomas [23]. Nonetheless, rearrangements and increased copies of MYC do
not appear to completely account for the high frequency of MYC overexpression
in CNS DLBCL observed by us and others [13].
The impact of MYC mutations, occurring as a consequence of aberrant somatic
hypermutation, on MYC protein expression in CNS DLBCL, remains unexplored
[15]. Exonic, hot spot mutations associated withMYC deregulation have not been
reported in CNS DLBCL. Thus, it remains unclear whether certain MYC
mutations could contribute to increased MYC protein expression in CNS DLBCL.
Activation of the NF-kB pathway, either directly or indirectly via activation of
the B-cell receptor pathway, could represent an alternative mechanism of MYC
deregulation in CNS DLBCL, since NF-kB is a known transcriptional activator of
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MYC [3]. In this context, similar to systemic ABC or non-GCB DLBCL and other
subtypes of B-cell lymphomas, a substantial number of CNS DLBCL harbor
chromosome 6q deletions (up to 71% in prior studies and 38% in our study),
which can result in the loss of at least two tumor suppressor genes (PRDM1 and
TNFAIP3) that have been shown to deregulate NF-kB activity [14, 24–26].
Mutations of genes associated with NF-kB activation (e.g., PRDM1, TNFAIP3,
MYD88, TBL1XR1) or the B-cell receptor signaling pathway (e.g., CD79b and
CARD11) could also lead to increased MYC expression in a subset of CNS DLBCL
[3, 24, 27, 28]. The limited number of cases with cytogenetic analysis in our study
and the lack of molecular analysis precluded assessment of this hypothesis. Future
studies integrating MYC protein expression with assays of NF-kB pathway
activation, in the context of the aforementioned chromosomal and genetic
alterations, would be worthwhile in determining their role in MYC overexpression
in CNS DLBCL.
Studies over the past couple of years have started to uncover complex genetic
and epigenetic mechanisms regulating MYC expression, stability, and function in
cancer, including lymphomas [29–32], and interrogation of these might shed light
on the mechanisms underlying MYC overexpression in CNS DLBCL. Rubenstein
et al. described increased MYC mRNA expression in CNS DLBCL compared to
nodal DLBCL by gene expression profiling (GEP) and quantitative RT-PCR
analysis [16]. However, Brunn et al. observed similar MYC mRNA levels as
described in systemic DLBCL on reevaluating their previously published GEP data
and therefore suggested post-transcriptional or post-translational mechanisms for
MYC deregulation in CNS DLBCL [4, 13]. Deregulation of MYC expression by
alterations of microRNAs is also conceivable. Numerous microRNAs have been
shown to positively or negatively modulate MYC expression [33–35]. Some MYC-
regulated microRNAs (miR-17-5p, miR-20a) have been shown to be upregulated
in CNS DLBCL [36]. However, a microRNA mediated pathway of MYC
overexpression has not yet been described in CNS DLBCL. Increased proliferation
may provide yet another alternative explanation for increased MYC expression in
CNS DLBCL, as MYC expression has been shown to be closely linked to the cell
cycle and is part of the ‘‘proliferation signature’’ in a variety of cancers
[29, 37, 38]. We observed a weak positive correlation between the Ki-67
proliferation index and MYC protein expression, while Brunn et al. observed a
stronger correlation [13]. Functional studies are, however, required to validate
these findings.
MYC rearrangements, either alone or in combination with BCL2 rearrange-
ments (‘‘double-hit’’ lymphomas), have been associated with resistance or a poor
response to therapy and inferior survival in systemic DLBCL [7–9, 39]. High MYC
and/or BCL2 protein expression, as assessed by immunohistochemistry, has also
been shown to have an adverse prognostic impact in systemic DLBCL,
independent ofMYC rearrangement and COO subtype [10–12]. In contrast,MYC
rearrangements have not thus far been shown to be prognostically relevant in CNS
DLBCL [13, 14]. The rarity of MYC translocation in our series did not allow for
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any meaningful analysis, and larger studies with uniformly treated patients will be
required to confirm or refute prior observations.
Data regarding MYC protein expression in CNS DLBCL is sparse [13, 17, 18].
Two older and smaller series comprising 14 and 27 CNS DLBCL reported MYC
expression in 0% and 50% of cases, respectively, with the latter suggesting an
association of MYC expression with adverse prognosis [17, 18]. It should be noted
that numerically defined cutoffs of MYC expression or overexpression were not
used in these studies. A recent report by Brunn et al. described MYC
overexpression (defined as .40% MYC expression) in 92% of their cases;
however, no associations with clinical outcomes were reported [13]. The prior
discrepant frequencies of MYC expression may be due to differences in reagents,
staining techniques, or patient populations studied [17, 18]. We did not observe
any associations between MYC expression and morphologic, immunophenotypic,
or clinical parameters including survival.
The relatively high frequency of BCL2 expression in our series (71%) is within
the range described previously (56–92%) [13, 40, 41]. An inconsistent association
of higher BCL2 expression with the non-GCB subtype has been reported in
systemic DLBCL, and BCL2 expression has been associated with translocations or
amplifications involving chromosome 18q21, the locus of BCL2 [10, 42]. Weber et
al. reported 18q gains in 37% of 19 cases of CNS DLBCL, but we and others did
not find +18q to be a significant recurrent abnormality [25, 26, 43]. Thus, at
present, the contribution of 18q gains to increased BCL2 expression in CNS
DLBCL remains unclear. An association between BCL2 expression and the non-
GCB COO subtype was seen in our series, but we did not observe an association of
BCL2 expression or MYC/BCL2 coexpression with any adverse clinical features.
Prior studies have reported a higher frequency of the non-GCB subtype in CNS
DBLCL (74%–97%) compared to systemic DLBCL (approximately 50%) [10, 40–
42, 44–47]. CNS DBLCL of non-GCB COO subtype accounted for a slightly lower
proportion of cases in our series (69%). Differences in antibodies, algorithms or
technical factors could possibly account for the different frequencies of COO
subtypes between our and prior studies. It is unclear whether CNS DBLCL with
the phenotype CD10+/BCL6+/MUM1/IRF4+, comprising 14% of our cases, were
classified as the non-GCB COO subtype in any of the previous reports.
Enrichment in cases of the non-GCB subtype has been suggested to contribute to
the poor prognosis of CNS DLBCL [40]. However, we did not detect any adverse
effect of COO subtype on survival, findings in line with studies by Hattab et al.
and Raoux et al. [45, 46].
A significantly decreased risk of death was observed in patients treated with
rituximab, irrespective of MYC expression levels. This finding further corrobo-
rates prior data showing improved survival of patients treated with rituximab in
CNS DLBCL [48–51]. Although we observed trends toward decreased risk of
relapse and death in patients treated with WBRT, no significant difference was
noted on multivariate analysis.
A variety of other prognostic biomarkers have previously been evaluated in
CNS DLBCL. Among these, a perivascular pattern of tumor cell infiltration has
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been associated with a poor prognosis [52]. In line with this finding, the
perivascular pattern of infiltration was an independent predictor of disease
progression in our series. We did not evaluate the presence of reactive perivascular
T cells, a feature that has been associated with superior overall survival [52, 53] or
the microvessel density, which as assessed by morphology or VEGF and endoglin
(CD105) expression has previously shown an inconsistent prognostic association
in CNS DLBCL [54–56]. A few prior studies reported an association of BCL6
expression with better prognosis; however, we and others did not observe such an
association [41, 57–62]. Finally, 6q deletions and homozygous 9p deletions have
been associated with significantly decreased PFS and OS [14, 24]. Due to the
limited number of cases analyzed, a statistically meaningful analysis could not be
performed in our series.
The strengths of our study include the relatively large number of cases of CNS
DLBCL analyzed for MYC expression, MYC/BCL2 coexpression, and COO
subtype. This is the largest series thus far to evaluate MYC expression in CNS
DLBCL and the first to assess the impact of MYC/BCL2 coexpression on clinical
outcomes. The outcomes and follow-up duration of our study are similar to or
higher than prior retrospective studies [45, 46, 63]. Comparisons of survival
outcomes between retrospective studies like ours (and many prior ones) and those
reporting results of prospective clinical trials, however, are not appropriate as
patients are highly selected in the latter. The limitations of our study include
incomplete data regarding therapy, clinical follow up, and cytogenetic and
molecular analyses to correlate with MYC protein expression. Lastly and
importantly, while we make several comparisons of CNS DLBCL with systemic
DLBCL, these should be interpreted with caution, as treatment regimens for these
two types of lymphoma are different. Further studies comprising larger numbers
of cases with complete genetic analyses and clinical follow up would be useful to
validate and expand upon our findings and help elucidate prognostically relevant
biomarkers.
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